White Pine Capital LLC acquired a new stake in AxoGen, Inc. (NASDAQ:AXGN – Free Report) in the third quarter, HoldingsChannel reports. The fund acquired 43,219 shares of the medical equipment provider’s stock, valued at approximately $1,812,000.
Several other institutional investors also recently modified their holdings of AXGN. Russell Investments Group Ltd. lifted its stake in AxoGen by 163.7% in the 3rd quarter. Russell Investments Group Ltd. now owns 334,902 shares of the medical equipment provider’s stock valued at $14,039,000 after purchasing an additional 207,916 shares during the last quarter. Lisanti Capital Growth LLC grew its holdings in AxoGen by 21.9% during the third quarter. Lisanti Capital Growth LLC now owns 110,420 shares of the medical equipment provider’s stock worth $4,629,000 after purchasing an additional 19,855 shares during the period. Advisor Resource Council grew its holdings in AxoGen by 6.8% during the third quarter. Advisor Resource Council now owns 8,749 shares of the medical equipment provider’s stock worth $367,000 after purchasing an additional 556 shares during the period. Calamos Advisors LLC increased its position in AxoGen by 15.8% during the third quarter. Calamos Advisors LLC now owns 110,210 shares of the medical equipment provider’s stock worth $4,620,000 after buying an additional 15,064 shares during the last quarter. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al increased its position in AxoGen by 46.0% during the third quarter. VIRGINIA RETIREMENT SYSTEMS ET Al now owns 30,150 shares of the medical equipment provider’s stock worth $1,264,000 after buying an additional 9,500 shares during the last quarter. 80.29% of the stock is currently owned by institutional investors and hedge funds.
Insiders Place Their Bets
In other AxoGen news, Director Joseph Tyndall sold 3,500 shares of the stock in a transaction dated Wednesday, September 2nd. The shares were sold at an average price of $49.70, for a total value of $173,950.00. Following the transaction, the director directly owned 10,650 shares of the company’s stock, valued at $529,305. This represents a 24.73% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 2.44% of the stock is currently owned by corporate insiders.
AxoGen Stock Performance
NASDAQ AXGN opened at $55.93 on Monday. The firm has a 50-day moving average of $43.27 and a 200-day moving average of $40.44. The company has a debt-to-equity ratio of 0.04, a quick ratio of 10.67 and a current ratio of 12.02. The stock has a market cap of $3.34 billion, a PE ratio of -86.05 and a beta of 1.21. AxoGen, Inc. has a 52-week low of $23.00 and a 52-week high of $59.72.
AxoGen (NASDAQ:AXGN – Get Free Report) last announced its earnings results on Wednesday, October 28th. The medical equipment provider reported $0.21 EPS for the quarter, topping the consensus estimate of $0.13 by $0.08. AxoGen had a negative net margin of 11.96% and a negative return on equity of 5.35%. The business had revenue of $75.83 million during the quarter, compared to the consensus estimate of $73.45 million. On average, sell-side analysts anticipate that AxoGen, Inc. will post -0.36 EPS for the current year.
Analysts Set New Price Targets
AXGN has been the topic of several research analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of AxoGen in a research note on Wednesday, August 26th. Morgan Stanley downgraded AxoGen to a “hold” rating in a research note on Tuesday, September 29th. Lake Street Capital reiterated a “buy” rating and set a $58.00 target price on shares of AxoGen in a research note on Thursday, October 29th. Raymond James Financial reissued an “outperform” rating and set a $57.00 target price on shares of AxoGen in a report on Thursday, October 29th. Finally, Leerink Partners boosted their target price on AxoGen from $52.00 to $56.00 and gave the stock an “outperform” rating in a report on Thursday, October 29th. Thirteen analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, AxoGen currently has a consensus rating of “Moderate Buy” and an average target price of $57.92.
Read Our Latest Stock Analysis on AXGN
About AxoGen
AxoGen, Inc. is a medical technology company focused on repairing peripheral nerve injuries—damage to nerves outside the brain and spinal cord. Its products are used by surgeons in procedures intended to restore nerve function and sensation. The company’s offerings include Avance Nerve Graft, a processed human nerve allograft used to bridge gaps in damaged nerves, and Axoguard products designed to protect, connect or cap nerves during repair. Axogen also provides education and support for healthcare professionals who use its nerve-repair solutions.
Read More
- Five stocks we like better than AxoGen
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Want to see what other hedge funds are holding AXGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AxoGen, Inc. (NASDAQ:AXGN – Free Report).
Receive News & Ratings for AxoGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AxoGen and related companies with MarketBeat.com's FREE daily email newsletter.
